Perspective Therapeutics Announces Acceptance of VMT-a-NET Data for Presentation at the AACR Annual Meeting 2026
Perspective Therapeutics Provides Recent Business Highlights and Reports Full Year 2025 Results
Perspective Therapeutics (NASDAQ:CATX) was upgraded by analysts at Piper Sandler to a "strong-buy" rating.
Perspective Therapeutics (NASDAQ:CATX) was given a new $16.00 price target on by analysts at Piper Sandler. They now have an "overweight" rating on the stock.
New Treatment Modalities Are Reaching Cancers That Resisted Everything Else